| dc.description.abstract | Objectives It has been proposed that zinc-?2-glycoprotein and S100A1 are possibly linked to the development of lipogenesis and obesity. We aimed to measure serum levels of S100A1 and zinc-?2-glycoprotein in patients with metabolic syndrome and investigate any associations of these two novel peptides with each other or components of metabolic syndrome. Methods Forty-four patients with metabolic syndrome and the equivalent number of healthy controls participated in this study. The participants' body mass index, waist circumference, systolic and diastolic blood pressure were measured. Serum levels of low- and high-density lipoprotein cholesterol, total cholesterol, triglyceride, fasting blood sugar, insulin, zinc-?2-glycoprotein and S100A1 protein were determined. Results Higher levels of anthropometric and lipid indices, metabolic factors and also SBP and DBP were observed in the metabolic syndrome group. Serum S100A1 levels were significantly lower in the metabolic syndrome group than the control group ( P?=?0.008). There was a strong positive correlation between serum zinc-?2-glycoprotein and S100A1 levels ( r?=?0.80, P?<?0.0001). Serum levels of both S100A1 ( P?=?0.03) and zinc-?2-glycoprotein ( P?=?0.02) were potentially higher in subjects with hypertension than those with normal blood pressure, though these were found as part of multiple testing. Conclusion The results indicate that changes in the circulating level of S100A1 protein occur in metabolic syndrome patients. The strong correlation between serum zinc-?2-glycoprotein and S100A1 might suggest that production or release of these two proteins could be related mechanistically. | |
